Sugi Predict

Sugi Predict / Targets / SMARCA2

SMARCA2

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 · P51531 · SMARCA2 on Sugi Atlas →

38,618 patent compounds predicted against SMARCA2, 21,306 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL119685 SCHEMBL119685 0.79 9/20
SCHEMBL1400789 SCHEMBL1400789 0.68 9/20
Purine Purine (SCHEMBL289481) 0.56 9/20
SCHEMBL1501665 SCHEMBL1501665 0.57 8/20
Purine Purine (SCHEMBL289483) 0.55 7/20
SCHEMBL1437084 SCHEMBL1437084 0.41 5/20
SCHEMBL1191366 SCHEMBL1191366 0.35 5/20
SCHEMBL123501 SCHEMBL123501 0.55 4/20
SCHEMBL1752787 SCHEMBL1752787 0.79 3/20
SCHEMBL1752784 SCHEMBL1752784 0.72 3/20
SCHEMBL531767 SCHEMBL531767 0.66 3/20
SCHEMBL1752783 SCHEMBL1752783 0.66 3/20
SCHEMBL1752810 SCHEMBL1752810 0.56 3/20
SCHEMBL1083968 SCHEMBL1083968 0.49 3/20
SCHEMBL1415496 SCHEMBL1415496 0.47 3/20
SCHEMBL1084456 SCHEMBL1084456 0.46 3/20
SCHEMBL1084759 SCHEMBL1084759 0.43 3/20
SCHEMBL1400930 SCHEMBL1400930 0.43 3/20
SCHEMBL1444761 SCHEMBL1444761 0.40 3/20
SCHEMBL1492751 SCHEMBL1492751 0.40 3/20

Clinical trials — most relevant to SMARCA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) PHASE3RECRUITING
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer. PHASE2NOT_YET_RECRUITING
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma PHASE2RECRUITING
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) PHASE2COMPLETED
A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. PHASE2NOT_YET_RECRUITING
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma PHASE2COMPLETED
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer PHASE2ACTIVE_NOT_RECRUITING
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE2RECRUITING
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma PHASE1/PHASE2WITHDRAWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation PHASE1COMPLETED
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Implementation of FEES in Spinal Muscle Atrophy nanCOMPLETED
Newborn Screening for Spinal Muscular Atrophy nanCOMPLETED
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA) nanCOMPLETED
Natural History Study of Smith-Magenis Syndrome nanACTIVE_NOT_RECRUITING
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC nanNOT_YET_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Palliative Care in Spinal Muscular Atrophy (SMA) 1 nanCOMPLETED
Adrenal& Bone Complications in Paediatric Patients Living With Spinal Muscular Atrophy (SMA) nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SMARCA2 binder may also engage these)

ProteinNameSimilarity
Q6DIC0 — 1.000 Q6DIC0 →
Q8K1P7 — 1.000 Q8K1P7 →
SMARCA4 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4 1.000 landscape →
Q3TKT4 — 1.000 Q3TKT4 →
A7Z019 — 1.000 A7Z019 →
P25439 — 0.999 P25439 →
Q58NQ4 — 0.997 Q58NQ4 →
G5EFF5 — 0.997 G5EFF5 →
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 0.996 landscape →
Q80TZ9 — 0.996 Q80TZ9 →
Q62901 — 0.996 Q62901 →
Q03468 — 0.996 Q03468 →
Q62431 — 0.996 Q62431 →
Q9H334 — 0.996 Q9H334 →
Q09228 — 0.996 Q09228 →
P83038 — 0.996 P83038 →
Q9NEL2 — 0.995 Q9NEL2 →
B3M301 — 0.995 B3M301 →
Q5QL03 — 0.995 Q5QL03 →
A2BEA6 — 0.995 A2BEA6 →
P24610 — 0.995 P24610 →
Q5HZJ0 — 0.995 Q5HZJ0 →
P0CF24 — 0.995 P0CF24 →
O35317 — 0.995 O35317 →
TNIK TRAF2 and NCK-interacting protein kinase 0.995 landscape →
P97820 — 0.995 P97820 →
Q2EJA0 — 0.995 Q2EJA0 →
P40645 — 0.995 P40645 →
P41846 — 0.994 P41846 →
P34333 — 0.994 P34333 →